DYNLT1 gene expression is downregulated in whole blood of patients at different Huntington's disease stages
Huntington's disease (HD) is a neurodegenerative disorder caused by a CAG nucleotide expansion, which encodes the amino acid glutamine, in the huntingtin gene. HD is characterized by motor, cognitive, and psychiatric dysfunctions. In a previous study, we showed by qPCR that some genes altered in an HD mouse model were also altered in blood of HD patients. These alterations were mainly with respect to the dynein family. Therefore, this study aimed to investigate whether dynein light chain Tctex type 1 (DYNLT1) is altered in HD patients and if there is a correlation between DYNLT1 gene expression changes and disease progression. We assessed the DYNLT1 gene expression in the blood of 19 HD patients and 20 healthy age-matched controls. Also, in 6 of these patients, we analyzed the DYNLT1 expression at two time points, 3 years apart. The DYNLT1 gene expression in the whole blood of HD patients was significantly downregulated and this difference was widened in later stages. These data suggest that DYNLT1 could emerge as a peripheral prognostic indicator in HD and, also, might be a target for potential intervention in the future.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology - 42(2021), 5 vom: 29. Mai, Seite 1963-1967 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rosseto, S M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomarker |
|---|
| Anmerkungen: |
Date Completed 14.05.2021 Date Revised 31.05.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s10072-020-04772-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM315665599 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM315665599 | ||
| 003 | DE-627 | ||
| 005 | 20231225155418.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10072-020-04772-0 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1052.xml |
| 035 | |a (DE-627)NLM315665599 | ||
| 035 | |a (NLM)32995988 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rosseto, S M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a DYNLT1 gene expression is downregulated in whole blood of patients at different Huntington's disease stages |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.05.2021 | ||
| 500 | |a Date Revised 31.05.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Huntington's disease (HD) is a neurodegenerative disorder caused by a CAG nucleotide expansion, which encodes the amino acid glutamine, in the huntingtin gene. HD is characterized by motor, cognitive, and psychiatric dysfunctions. In a previous study, we showed by qPCR that some genes altered in an HD mouse model were also altered in blood of HD patients. These alterations were mainly with respect to the dynein family. Therefore, this study aimed to investigate whether dynein light chain Tctex type 1 (DYNLT1) is altered in HD patients and if there is a correlation between DYNLT1 gene expression changes and disease progression. We assessed the DYNLT1 gene expression in the blood of 19 HD patients and 20 healthy age-matched controls. Also, in 6 of these patients, we analyzed the DYNLT1 expression at two time points, 3 years apart. The DYNLT1 gene expression in the whole blood of HD patients was significantly downregulated and this difference was widened in later stages. These data suggest that DYNLT1 could emerge as a peripheral prognostic indicator in HD and, also, might be a target for potential intervention in the future | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Biomarker | |
| 650 | 4 | |a DYNLT1 | |
| 650 | 4 | |a Gene expression | |
| 650 | 4 | |a Huntington’s disease | |
| 650 | 7 | |a DYNLT1 protein, human |2 NLM | |
| 650 | 7 | |a Huntingtin Protein |2 NLM | |
| 650 | 7 | |a Dyneins |2 NLM | |
| 650 | 7 | |a EC 3.6.4.2 |2 NLM | |
| 700 | 1 | |a Alarcon, T A |e verfasserin |4 aut | |
| 700 | 1 | |a Rocha, D M C |e verfasserin |4 aut | |
| 700 | 1 | |a Ribeiro, F M |e verfasserin |4 aut | |
| 700 | 1 | |a Ferguson, S S G |e verfasserin |4 aut | |
| 700 | 1 | |a Martins-Silva, C |e verfasserin |4 aut | |
| 700 | 1 | |a Muniz, M R |e verfasserin |4 aut | |
| 700 | 1 | |a Costa, P F |e verfasserin |4 aut | |
| 700 | 1 | |a Guimarães, D A |e verfasserin |4 aut | |
| 700 | 1 | |a Pires, Rita G W |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology |d 2000 |g 42(2021), 5 vom: 29. Mai, Seite 1963-1967 |w (DE-627)NLM108608468 |x 1590-3478 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2021 |g number:5 |g day:29 |g month:05 |g pages:1963-1967 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10072-020-04772-0 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2021 |e 5 |b 29 |c 05 |h 1963-1967 | ||